Age-Related Inflammation: the Contribution of Different Organs, Tissues and

Systems. How to Face it for Therapeutic Approaches by Cevenini, E. et al.
 Current Pharmaceutical Design, 2010, 16, 609-618 609 
 1381-6128/10 $55.00+.00  © 2010 Bentham Science Publishers Ltd. 
Age-Related Inflammation: the Contribution of Different Organs, Tissues and 
Systems. How to Face it for Therapeutic Approaches 
E. Cevenini
1
, C. Caruso
2
, G. Candore
2
, M. Capri
1
, D. Nuzzo
3
, G. Duro
3
, C. Rizzo
2
, G. Colonna-Romano
2
, D. 
Lio
2
, D. Di Carlo
2
, M. G. Palmas
1
, M. Scurti
1
, E. Pini
1
, C. Franceschi
1
 and S. Vasto
2,*
 
1
Department of Experimental Pathology and C.I.G. - Interdepartmental Center "L. Galvani" for Integrated Studies on Bioinformatics, 
Biophysics, and Biocomplexity, University of Bologna; 
2
Immunosenescence Unit, Department of Pathobiology and Biomedical 
Methodologies, University of Palermo; 
3
IBIM, National Research Council, Palermo, Italy 
Abstract: A typical feature of ageing is a chronic, low-grade inflammation characterized by a general increase in the production of pro-
inflammatory cytokines and inflammatory markers (“inflamm-ageing”). This status may slowly damage one or several organs, especially 
when unfavorable genetic polymorphisms and epigenetic alterations are concomitant, leading to an increased risk of frailty together with 
the onset of age-related chronic diseases. The contribution of different tissues (adipose tissue, muscle), organs (brain, liver), immune 
system and ecosystems (gut microbiota) to age-related inflammation (“inflamm-ageing”) will be discussed in this review in the context of 
its onset/progression leading to site-restricted and systemic effects. Moreover, some of the possible strategies and therapies to counteract 
the different sources of molecular mediators which lead to the age-related inflammatory phenotype will be presented. 
Keywords: Ageing, age-related diseases, immunosenescence, inflammation. 
1. INFLAMMATION AND AGEING  
 Ageing, an inexorable intrinsic process that affects all cells, 
tissues, organs and individuals, is a post-maturational process that, 
due to a diminished homeostasis and increased organism frailty, 
causes a reduction of the response to environmental stimuli and, in 
general, is associated to an increased predisposition to illness and 
death [1].  
 A typical feature of ageing process is the development of a 
chronic, low grade, inflammatory status referred to as “inflamm-
ageing” [2-4] and this condition has emerged as critical in the onset 
of sarcopenia, frailty and the pathogenesis of several age-related 
chronic diseases, such as Parkinson's and Alzheimer's disease (AD), 
atherosclerosis and type 2 diabetes [5-9]. All these diseases (and 
disabilities) appear to share the same process of inflammation, 
leading to the concept of an age-related diseasome [10]. So, genes 
and epigenetic factors involved in the regulatory pattern of inflam-
mation should play a role in human ageing, in fact many functional 
cytokine polymorphisms were found as associated to unsuccessful 
ageing or longevity [11]. Furthermore high serological levels of 
pro-inflammatory mediators like cytokines and c reactive protein 
(CRP) seem to be the marker of unsuccessful ageing, as recently 
reviewed [1,5]. 
 Actually, inflammation is a systemic physiological process 
fundamental for survival, which involves a variety of cells and 
organs but its persistence over years/decades and deregulation 
favour the onset of several age-related diseases as previously stated. 
On the whole, the possibility to counteract these pathologies 
represents one of the most important biomedical and public health 
challenges [12]. Despite its enormous complexity, involving 
combinations of genetic, epigenetic, environmental and stochastic 
factors, a few basic molecular mechanisms appear to underpin the 
ageing process, involving a set of highly conserved mechanisms 
[13]. One of these seems likely to be inflammation, as previously 
stated. In particular, a variety of tissues (adipose tissue, muscle), 
organs (brain, liver), systems (immune system) and ecosystems (gut  
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microbiota) of the body contribute in a different manner to 
inflamm-ageing onset/progression with specific site or organs-
restricted effects and systemic effects, as shown in Fig. (1) and 
discussed later. 
 This review will deal with the major findings regarding the 
sources of the inflammatory stimuli underpinning and sustaining 
age-related inflammation together with the possible strategies to 
counteract the inflammatory status. In this context the role of 
senescent-associated secretory phenotype will be not deeply consi-
dered since it is beyond the scope of the review. 
2. POSSIBLE CONTRIBUTORS TO THE INFLAMMATORY 
PHENOTYPE THAT OCCURS WITH AGE  
2.1. Immune System  
 During ageing the immune systems is progressively remodelled 
with changes in a dynamic process which mainly depends on the 
evolutionarily unpredicted, chronic lifelong persisting antigenic 
load (immunosenescence) [14]. Indeed, there is a link between indi-
vidual exposure to past infection, levels of chronic inflammation 
and increased risk of heart attack, stroke, AD and cancer. Notably, 
CRP levels are correlated with the number of seropositivities to 
common pathogens, suggestive of infection history [5,9,15,16]. 
However, an age-related increase in the production of inflammatory 
compounds occurs in the immune system and one of the leading 
causes of death in very elderly are persistent infections, including 
Epstein Barr virus and cytomegalovirus (CMV) [17]. CMV is 
amongst the largest and most complex of known viruses and 
chronic CMV infection actually plays a major role in immuno-
senescence, indeed the immune system in old people is full of 
megaclones specific for CMV epitopes [18]. Healthy seropositive 
subjects aged 19-55 years are able to maintain CMV under control 
by broadly targeting the overall CMV proteome with about 10% of 
both CD4
+
 and CD8
+
 peripheral T cells which produce intracellular 
interferon (IFN)- [19]; however a much larger percentage (20-
50%) of T cells are involved in protecting the elderly from CMV 
endogenous reactivation. Such an enormous and stable burden of 
effector CD4
+
 and CD8
+ 
T cells producing IFN- and tumor 
necrosis factor (TNF)- may contribute to inflamm-ageing [20].  
 This evidence indicates that the evolutionarily “negotiated” 
balance between viral mechanisms of pathogenesis, persistence and 
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immune evasion and the host cellular immune response may be 
profoundly altered in very old people; our immune system is quite 
efficient in coping with acute infections in young people, but the 
same system is not particularly efficient in responding to chronic 
stimuli, particularly when it occurs in old subjects. Furthermore, 
chronic CMV infection is associated with frailty, a state with 
increased morbidity and mortality in older adults, and inflammation 
status, measured in terms of interleukin (IL)-6 levels, enhances this 
effect [21].  
 The most recent studies on immunosenescence have been 
devoted to the identification of an Immune Risk Phenotype (IRP), 
informative and predictive for morbidity and mortality in the 
elderly [22,23]. It is characterized by a CD4/CD8 of < 1 owing to 
an accumulation of late stage differentiated CD8 cells many of 
which are specific for CMV antigens. CMV infection and high plas-
ma level of pro-inflammatory cytokine (such as IL-6) are biomar-
kers of immunosenescence affecting inexorably human immunity 
[24]. 
 In addition genetics impacts on immune system response during 
ageing. It is demonstrated that functional cytokine gene poly-
morphisms influence the cytokine production, playing a role as 
susceptibility or resistance factors against immune-mediated and 
infectious disease. That is the case, amongst other, of genetic 
variations in the -308A/G locus for TNF- and the -308A allele 
which may be one of the susceptibility factor for infectious diseases 
in old persons, particularly considering its association with the 
increased release of pro-inflammatory cytokines and with the 
reduction of zinc release and methallothionin, fundamental for the 
inflammatory response [25]. Most generally, as previously concep-
tualised [2], specific genetic variants associated to a persistent pro-
inflammatory status can favour the onset of age-related diseases.  
2.2. Gut Microbiota 
 Current research on human gut microbiota states that the size of 
this ecosystem, consisting of about 100 trillions of microbial cells 
and an "extended genome" of millions of microbial genes (the 
microbiome), is around 10 times greater than the total number of 
somatic and germ line cells. Because this complex symbiosis 
influences host metabolism, physiology, and gene expression, it has 
been proposed that humans are complex biologic "superorganisms." 
[26-28].  
 Gut microbiota and gastrointestinal-associated immune system 
coexist in a balanced microenvironment where cytokines and lym-
phocytes have to cope with the antigenic load, in order to control 
the enormous variety of bacterial species within the intestinal 
microflora. This physiological condition where bacteria and their 
products have to be tightly surveyed by immune cells may have a 
profound impact on human health, influencing the nutritional, 
physiological and immunological status of the host [29,30]. 
Specifically, the production of potentially toxic compounds (xeno-
biotics) either ingested with the diet or locally produced as a 
consequence of the microbial metabolism may affect host health 
condition [31]. Indeed, gut microbiota affects various charac-
teristics of the host (fat storage, obesity) [28,32,33] and intestinal 
disorders such as the irritable bowel syndrome, inflammatory bowel 
disease and colon cancer [34-36].  
 Furthermore, a profound derangement of intestinal microflora is 
present in frail elderly people and may contribute to the age-related 
inflammatory status. This derangement of the intestinal microflora 
likely represents an important source of continuous antigenic 
stimulation and contributes to immunosenescence. Therefore, on 
the basis of its potential importance as a major source of chronic 
stimuli (immunological/inflammatory/toxic/metabolic) to other 
organs and systems, such as immune system and liver, we can 
surmise that age-related changes of composition and function of the 
gut microbiota may play a major role in the development and 
maintenance of inflamm-ageing. At present, a study on gut 
microbiota composition shows that three main modifications occur 
in faecal microbiota from old frail subjects: a 26-fold reduction in 
the number of lactobacilli (which stimulate immune functions and 
help the nutrient absorption), a 3-fold reduction in the number of 
bacteriodes (which digest polysaccarides, some species are oppor-
tunist pathogens) and a 7-fold increase in the number of entero-
bacteriacee (potentially pathogens) [37]. Differences in faecal 
microbiota were also found in a study on people of different 
countries and ages, including aged and long-lived people [38].  
 Therefore, the elucidation of the intestinal microbiome is likely 
to underpin future disease prevention strategies, personalized health 
care regimens, and the development of novel therapeutic inter-
ventions that takes into account the complex genetic scenario 
including genes embedded in human affiliated microbiome, accoun-
ting alone for > 100 times as many genes as those of the human 
genome [39,40]. 
2.3. Adipose Tissue  
 Recent studies on adipogenesis show the haematopoietic origin 
of adipocytes [41] which can directly produce a series of peptides 
named adipokines. 
 It has been demonstrated that the adipose tissue increases 
quantitatively with age throughout the body, including organs such 
as liver and bone marrow, and it actively contributes to the 
establishment of the chronic low-grade systemic inflammation, by 
producing high level of adipokines [42]. This augmented body fat is 
characterized by increased visceral adiposity and it occurs despite 
the decreased subcutaneous fat and progressive sarcopenia typical 
of ageing. In particular, visceral adiposity, characteristic of obesity, 
has been associated with greater risks for age-related diseases, 
including insulin resistance, type 2 diabetes, metabolic syndrome, 
fatty liver disease, atherosclerosis, degenerative disorders including 
dementia, airway disease and some cancers [43]. 
 Obese adipose tissue is characterized by progressive infiltration 
of macrophages as obesity develops and these macrophages are an 
important source of inflammation in this tissue [44]. The infiltration 
of macrophage can occur through different mechanisms. In obesity, 
adipocytes begin to secrete low levels of TNF-, which can 
stimulate preadipocytes to produce monocyte chemoattractant 
protein-1 (MCP)-1 which attracts macrophages. Similarly, endo-
thelial cells also secrete MCP-1 in response to cytokines. Thus, 
either preadipocytes or endothelial cells could be responsible for 
attracting macrophages to adipose tissue. Increased secretion of 
leptin (and/or decreased production of adiponectin) by adipocytes 
may also contribute to macrophage accumulation by stimulating 
transport of macrophages to adipose tissue and promoting adhesion 
of macrophages to endothelial cells. This condition appears to be 
very similar to that seen in atherosclerosis [45].  
 Whatever the initial stimulus to recruit macrophages into 
adipose tissue is, these cells along with adipocytes and other cell 
types could perpetuate a vicious cycle of their recruitment, the 
production of inflammatory cytokines, and the impairment of 
adipocyte function [46]. Furthermore, obesity is tightly correlated 
to insulin resistance by the adipose tissue production of pro-
inflammatory TNF-, that is overexpressed in obese animals and 
humans [47]. The activation of proinflammatory pathways after 
exposure to TNF- induces a state of insulin resistance in terms of 
glucose uptake in adipocytes that impair insulin signalling at the 
level of the insulin receptor substrate proteins, as recently reviewed 
[48,49]. This results are further confirmed in obese mice lacking 
TNF- or its receptor that show protection against developing 
insulin resistance [50]. 
 Despite the great amount of data showing the contribution of 
adipose tissue to inflammation, it has not yet clarified if it is active 
also in normal weight individuals and if the visceral adipose tissue 
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is a source of inflammation in any case or only under specific 
condition.  
2.4. Muscle 
 In the elderly, muscles become atrophic (loss in muscle mass) 
and weaker (loss in muscle force), more susceptible to damage and 
consequently the regeneration and recover occur more slowly than 
was the case in youth. This condition leads to sarcopenia, the age-
related loss of skeletal muscle mass, which can start as early as 30 
years of age. It can result in a loss of about 30-50% of the muscle 
mass by the age of 80 years, in a progressive decline of movement 
speed and reaction times [51]. Due to the ongoing ageing of 
Western populations the prevalence of sarcopenia is expected to 
dramatically increase, thus each strategy to counteract this age-
related muscle loss is strongly pursued.  
 The biological mechanisms responsible for sarcopenia are 
complex. In elderly, there is a decline in a variety of neural, 
hormonal, and environmental trophic signals to muscle. The most 
important endogenous cause may be the irreversible age-related 
loss of -motor units in the central nervous system, on the other 
hand the most important environmental cause of sarcopenia is the 
lack of physical activity with its beneficial effects in terms of anti-
inflammatory regulators [52]. 
 Serum levels of testosterone, estrogens and androgens decline 
with age and they are known to be involved in the decrease of 
muscle mass [53]. All these aspects can modify downstream cell 
signaling, decreased protein synthesis and a decreased ability of the 
muscle stem cells (the satellite cells) to repair and maintain muscle 
mass [54]. Among the various factors involved in the aetiology of 
muscle weakness and sarcopenia, it seems clear that chronic 
inflammation also plays a major role [2,55]. In fact there is 
increasing evidence that a raise of inflammatory cytokines, possibly 
in combination with reduced growth factor levels, contributes to the 
development of sarcopenia and age-related physical decline [56,57]. 
Furthermore epidemiological studies have shown that there is a 
correlation between high levels of inflammatory markers (such as 
IL-6 and CRP), low levels of insulin growth factor (IGF)-1, high 
levels of oxidative stress, decreased mitochondrial function and 
muscle weakness [58-60]. Alongside, a correlation between 
hormonal reduction and inflammation is present, since estrogen 
decline seems to increase the levels of pro-inflammatory cytokines 
such as IL-6 and TNF- [61]. 
 Epidemiological studies have reported that IL-6 is strongly 
associated with functional disability and loss of muscle mass but 
experimental studies have not been able to link IL-6 to sarcopenia 
[58,62], even if in vitro cellular models showed that IL-6 down-
regulates IGF-1 and in turn the effect of low IGF-1 levels may 
stimulate IL-6, suggesting a biological link between IGF-1, IL-6 
and estrogen [63]. However, human investigations have shown that 
inflammation impairs muscle strength in elderly people [64] while 
IGF-1 and IL-6 plasma levels were synergistically related to 
disability and mortality in older women [56]. In this context, it is 
worth noting to outline that the muscle restricted IGF-1 (mIGF-1) 
plays a fundamental role in muscle growth and remodelling [65]. It 
has been demonstrated that mIGF-1 transgene accelerates the 
regenerative process of injured skeletal muscle, modulating the 
inflammatory response, and limiting fibrosis. At the molecular 
level, mIGF-1 expression significantly down-regulates pro-inflam-
matory cytokines, such as TNF- and IL-1, and modulates the 
expression of chemokines. In addition, mIGF-1 expression modu-
lates key players of inflammatory response, such as macrophage 
migration inhibitory factor (MIF), high mobility group protein-1, 
and transcription factor NF-B [65].  
 However, the situation is much more complex because it is 
emerging that some cytokines, such as IL-6, appear to have context-
specific pro- or anti- inflammatory effects. To this regard, it has 
been demonstrated that during and after exercise IL-6 is produced 
and released by muscle fibres: IL-6 stimulates the appearance in the 
circulation of other anti-inflammatory cytokines such as IL-1ra and 
IL-10 and inhibits the production of the pro-inflammatory cytokine 
TNF- [66].  
 In addition, IL-6 was introduced as the first myokine, that is 
produced and released by contracting skeletal muscle fibres, 
exerting its effects in other organs of the body. Myokines may be 
involved in mediating beneficial health effects against chronic 
diseases associated with low-grade inflammation such as diabetes 
and cardiovascular diseases. In this case IL-6 is an anti-inflam-
matory signalling molecule, leading to increased lipolysis, 
increased glucose uptake and decreased inflammatory response [67-
69].  
 Therefore in this multifaceted contest, we suggest that there is a 
trade-off between the inflammatory status that tends to decrease 
muscle mass and the anti-inflammation factors, that, on the other 
side, tend to increase muscle mass. It is on this microenvironment 
that possible strategies could be applied for sustaining more 
efficient muscle regeneration and repair. 
2.5. Brain 
 Normal brain ageing is associated with chronic low-grade 
inflammation. A growing amount of literature is related to the 
development of dementia and particularly Alzheimer’s Disease 
(AD). AD is a heterogeneous and progressive neurodegenerative 
disease that in Western societies accounts for the majority of 
clinical senile dementia. Many inflammatory mediators have been 
detected in regions of the brain of patients with AD and astrocyte 
and microglial cells activation has a fundamental role in the inflam-
matory pathogenesis, as stated by the amyloid cascade/neuroin-
flammation hypothesis [70]. Astrocytes are responsible for the 
production of the neurotoxic substances, such as reactive oxygen 
and nitrogen species, pro-inflammatory cytokines, complement 
proteins, and other inflammatory mediators that bring important 
neurodegenerative changes [71]. The microglia activation can be 
due to local or systemic inflammation. In fact a strong local 
inflammatory stimulus such as a previous head trauma is a risk 
factor for AD and several epidemiological studies clearly show that 
blood elevations of acute phase proteins, markers of systemic 
inflammatory stimuli, may be risk factors for cognitive decline and 
dementia [72-74]. 
 It has been seen that several genetic and environmental factors 
are involved in AD onset as recently reviewed [75], thus confirming 
that the inflammatory status cannot be per se the only “hit” or 
condition able to force the development of the pathogenesis [2].  
 However, several data demonstrate that immune-inflammatory 
parameters are modified in blood lymphocytes obtained from AD 
patients and stimulated in vitro by amyloid [76]. Data on invol-
vement of the immune system in AD are controversial and difficult 
to fully understand. The results obtained in these studies can, on 
one hand, be the mirror of lymphocytes T and microglial locally 
activated in brain AD patients, on the other hand the activation of 
peripheral lymphocytes might be the result of the systemic 
activation of immune-inflammation. 
2.6. Liver 
 There are very few experimental data on age-dependent 
changes in human liver, and they are mainly related to its mor-
phological and histological modifications, together with functional 
decline of mitochondria in hepatocytes [77]. Human liver appears 
to preserve its function relatively well [78], but the evaluation of 
the role of the liver in age-related inflammation, its ageing rate are 
scanty and unsatisfactory [79]. Surprisingly, clinical data indicate 
that liver grafts from aged donors (also over 90 years) have 
functionality and graft duration comparable to those achievable 
with liver grafts from young donors [80]. These clinical and surgery 
data could be suggest that human liver ageing undergoes a 
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negligible age-related changes. On the other side, many factors 
could influence the biological age of the organ, such as hepatitis, 
virus infectious, diet, alcohol consumption, regeneration capacity 
and pro- or anti-inflammatory microenvironment. This last factor is 
particularly interesting for the purpose of the present review, and it 
could be due also to the function and activation of Kupffer cells, 
which account for 80%–90% of the body’s resident macrophages 
[81]. It appears to be maintained or even increased in old age 
(Kupffer cell numbers: 3-fold; activity: 5-fold) with important 
implications both for site-restricted inflammatory responses [82].  
 In addition, the tightly connection between gut microbiota and 
liver is still poorly understood. There are various alterations of the 
gastrointestinal tract in liver disease and portal hypertension, which 
might be less clinically overt than potentially life-threatening 
features, such as ascites. However, these alterations, for example 
gut-barrier dysfunction and alterations of gut microbiota, have a 
great impact on the portal enteropathy, as they both contribute to 
the systemic inflammation in liver cirrhosis, which is considered a 
risk factor for infections as well as the development of cachexia 
[83].  
 Very recently, the role of the liver towards the cell-mediate 
immune response has been addressed in mice model and data 
obtained indicate that liver has the potential to “remember” its 
lymphoid function [84], thus opening new hypothesis on liver 
contribution to inflammatory status both at organ and systemic level 
in a suggestive fashion.  
3. POSSIBLE AD HOC STRATEGIES TO COUNTERACT 
THE INFLAMMATORY STATUS 
3.1. Vaccinations  
 Because lifelong, acute or chronic exposure to bacteria, viruses, 
and other pathogens or antigens can induce a progressive increase 
of the inflammatory status during ageing, any procedure aimed at 
avoiding immunological extra burden is highly recommended for 
elderly individuals. First of all, careful attention should be paid to 
neglected sources of antigenic stimulation, such as chronic, 
subclinical infections in the oral cavity and the gastrointestinal and 
urogenital tracts, amongst others, which probably represent a major 
source of chronic antigenic stimulation. From this point of view, a 
systematic search for chronic infections, and the setup of safe 
procedures to eradicate them, would be likely to have a strong, 
beneficial impact on health status and functional capability, but also 
on overall survival and life span in the elderly [39]. 
 Another strategy to counteract immunosenescence is to reduce 
as much as possible the antigenic load represented by common 
infectious agents such as influenza virus, hepatitis viruses and 
CMV, amongst others. Strategies of specific vaccination should be 
applied to prevent, not only morbidity and mortality, but also any 
additional persistent stimulation of the immune system in the 
elderly [85,86] However, the antibody response to influenza vac-
cine in the elderly is considerably lower than in younger adults 
[87], and the efficacy and effectiveness of vaccine in elderly 
individuals living in a community seem to have a modest impact in 
meta-analysis studies [88]. In addition, some published data suggest 
a correlation between CMV-seropositivity, chronic pro-inflam-
matory activity, and non-responsiveness to the anti-influenza 
vaccine. This phenomenon appears to be age independent, even if 
more pronounced in elderly subjects [89]. Because CMV seems to 
be one of the main driving force of immunosenescence, and 
because the number of CMV
+
 subjects increase with age, the 
possibility of administrating large-scale vaccination against CMV 
early in life should be envisaged. Indeed, immunization strategies 
against CMV could be potentially highly protective, as they should 
avoid the accumulation of terminally differentiated T cell mega-
clones. However, anti-CMV adoptive immunotherapies [90,91] are 
nowadays not satisfactory because they are insufficient to provide a 
long-lasting resistance to CMV, and further studies are urgently 
needed for more effective anti-CMV vaccines. Many groups are 
presently developing new approaches which seem to be more 
promising than previous procedures [92]. However, any large-scale 
immunization strategy in the elderly has to face the additional 
problem of the before mentioned age-related changes in B and T 
cell subsets, which in turn interfere with the effectiveness of 
vaccination. There is a specific need for the development of an ad 
hoc vaccine appropriate for the elderly and their immune status. 
 A further strategy to improve the immune system in elderly, 
and so also lowering the pro-inflammatory status, could be the 
deletion of T megaclones, which are poorly responding cells that 
produce inflammatory cytokines and contribute to the IRP [93]. The 
selective elimination of these megaclones could theoretically be 
performed by purging techniques [94-97], specifically upgraded 
with antibodies/tetramer complex, that recognize the different 
megaclones. However, it is evident that these approaches in 
humans, especially in elderly individuals, are not easily practicable. 
On the other hand the emptying of the immunological space, 
consequent to the removal of the megaclones, in turn could trigger 
the homeostatic proliferation of the remnant memory T cell clones, 
frustrating the attempt to eliminate them [98,99]. In addition, naive 
T lymphocytes may acquire a phenotype similar to antigen-
experienced memory T cells, but this type of cells are not sufficient 
to mediate an effective immune response, as recently demonstrated 
in mouse model [100]. 
 Further investigations have to be addressed towards a 
personalised therapy such as the genetic screening of subjects more 
susceptible to acute and/or recurrent infectious diseases (HLA 
subgroups) and the administration of vaccines constituted only by 
HLA-restricted immunodominant peptides.  
3.2. Probiotic Treatment 
 The derangement of the intestinal microflora that occurs with 
age seems likely to represent an important source of continuous 
antigenic stimulation which contributes to immunosenescence. 
Optimal gut microbiota may play a role as anti-inflammatory agents 
contributing to late life survival in good health, therefore tools for 
large-scale monitoring of such age-associated derangement and 
specific strategies to reconstitute the normal microflora in the 
elderly are urgently needed and should represent a priority in 
ageing research. A large body of literature on possible therapeutic 
manipulation of the normal flora in enteric diseases is available, and 
experimental treatments with bacterial unmethylated cytosine-
guanine (CpG)-DNA sequences that have immunostimulatory 
effects, have been recently published and represent an interesting 
perspective for future therapies in the enteropathies [101] Data from 
animal models testing the efficacy of probiotic treatment for 
inflammatory bowel disease seem to be very promising [102], and 
recent data obtained in in vitro experiments suggest that 
Bifidobacterium genomic DNA up-regulates the secretion of anti-
inflammatory IL-10 by peripheral blood mononuclear cells [103]. 
Bacteria could also be exploited by genetic engineering in order to 
deliver anti-inflammatory cytokines or other biologically active 
molecules to the gut. To this purpose, efficacy tests of these 
approaches have been done in mice with Lactobacillus lactis 
engineered to secrete IL-10 or single-chain antibodies for pathogen-
specific passive immunity [104].  
 The propensity of the intestinal immune system to generate 
tolerance to non-invasive antigens is well known, and this is a 
formidable challenge for the development of novel orally active 
vaccines. Oral tolerance is finely tuned because mucosal surfaces 
also represent a major site of pathogen entry, and the immune 
system is able to mount an effective response to protect the body 
from invading microorganisms, while maintaining tolerance to 
“harmless” antigens. In order to avoid the onset of possible auto-
immune phenomena, any procedure aimed to increase immunity at 
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the mucosal level should not interfere with physiological mecha-
nisms of tolerance to luminal antigens in the gut, whose alteration 
may lead to immune-mediated pathology, such as Crohn’s disease 
and ulcerative colitis. In any case, this antiimmunosenescence 
strategy needs further knowledge of dendritic cells and of their role 
in oral tolerance. A wide range on dendritic subpopulations is 
present at the mucosal immune system, some of the lineage and 
subset being still poorly known [39,40]. 
3.3. Non Steroidal Anti-Inflammatory Drugs (NSAIDs)  
 The age associated increase in pro-inflammatory cytokines in 
the elderly, raises the possibility that some pro-inflammatory cyto-
kine blocking antibodies or soluble receptors could also beneficial 
for elderly. Moreover, there are other less potent well-known 
inflammation-modulating drugs, such as statins and NSAIDs that 
have few side effects and can be used with safety even in very old 
subjects. On the basis of this, it is reasonable to assume that anti-
inflammatory treatments could be useful to counteract and to reduce 
the age-dependent inflammatory status, preventing the development 
of age-related inflammatory diseases. In particular, several 
epidemiological studies have suggested that long-term treatment 
with NSAIDs may reduce the risk of developing AD [74]. On the 
other hand, a recent report based on a longitudinal study of men and 
women aged 70 years and older with a family history of AD 
(ADAPT study) showed that use of naproxen or celecoxib did not 
improve cognitive function. However, several critical issues have 
been raised concerning the study results, i.e. it has been claimed 
that the ADAPT study does not indicate that NSAIDs, if taken 
during adulthood and for an extended period, cannot prevent or 
delay the onset of dementia [105,106]. On the other hand, it has 
been seen that statins reduce amyloid-mediated microglia neuro-
toxicity in vitro independently from cholesterol lowering, providing 
a rationale for their use in AD. However, contrasting therapeutic 
results have been obtained, so additional studies are necessary to 
definitively assess the effects of statins on AD. 
 Epidemiological studies have shown that prolonged aspirin 
ingestion reduces the incidence of prostate cancer. This effect might 
result, at least in part, from Cyclo-oxygenase(COX)-2 inhibition. 
However, it is possible that the anti-cancer activity of these 
compounds might also reflect COX-independent effects, since high 
concentrations of NSAIDs suppress the growth of cells in culture 
that do not express COX-2 [107]. 
3.4. Diet 
 It is becoming clearer how food intake and life style can 
influence life span. If on the one hand protein-malnutrition is cited 
as the major cause of immunodeficiency worldwide, on the other 
hand high fat intake is the major cause of metabolic inflammatory 
disease. So weight control and nutrient analysis can contribute to 
protect against chronic inflammation and metabolic complications 
(e.g., visceral obesity, type 2 diabetes and atherosclerosis). High 
intake of meat and total protein and lower intake of fruit, vegetables 
are associated with increased risk of inflammatory arthritis whereas 
a Mediterranean type diet might have a protective role [108]. Fat 
intake seems to be associated with ulcerative colitis whereas fruit, 
vegetables and fiber consumption decrease the risk of inflammatory 
bowel disease [109]. A study on Mediterranean diet and inflam-
matory markers have revealed that participants closer to the 
Mediterranean diet have lower levels of CRP, IL-6, fibrinogen and 
white blood cell counts [110]. By comparison, Lopez-garcia and 
collaborators [111] revealed high levels of CRP and other inflam-
matory molecules among people which diet was characterized by 
red and processed meat, sweets, desserts, French fries and refined 
grains. So the Mediterranean diet might be effective in reducing the 
prevalence of metabolic syndrome and associated pro-inflammatory 
status. In addition, it seems to be associated with increased survival 
among older people [112]. 
 In modern diets, there are few sources of omega-3 fatty acids, 
mainly the fat of cold water fish such as salmon, sardines, herring, 
mackerel, black cod, and bluefish. Specifically, there are two 
critical omega-3 fatty acids, (eicosapentaenoic acid and docosa-
hexaenoic acid), that the body needs. By contrast, sources of 
omega-6 fatty acids are numerous in modern diets. They are found 
in seeds and nuts, and the oils extracted from them. Refined 
vegetable oils, such as soy oil, are used in most of the snack foods, 
cookies, crackers, and sweets in the American diet as well as in fast 
food. The body also constructs mediators from omega 6 fatty acids. 
In general, those derived from the two classes of essential fatty 
acids have opposite effects. Those from omega-6 fatty acids tend to 
increase inflammation, blood clotting, and cell proliferation, while 
those from omega-3 fatty acids decrease those functions. Both 
families must be in balance to maintain optimum health [113-115]. 
 Finally, a correct dietary intake (sometimes supplemented by 
minerals or vitamins) in the elderly should be considered as a 
fundamental factor necessary to improve the health status of the 
immune system. Actually, it was shown that the dietary supple-
mentation with the recommended daily intakes of zinc for 1 or 2 
months decreases the incidence of infections and increases the rate 
of survival to further infections in elderly people [116]. 
 In the last years, because calorie restriction has been shown to 
increase maximum life span in several species (not yet in humans), 
there has been increasing interest in the potential therapeutic use of 
calorie restriction as a strategy to decrease pro-inflammatory 
molecules and or increase anti-inflammatory regulators. To this 
regard, calorie restriction has been demonstrated to down-regulate 
inflammatory genes and decrease blood inflammatory markers 
[117]. However, there is no evidence that low calorie intake in the 
elderly is associated with longevity; in fact a moderate overweight 
in clinics is the best prognosis for a good outcome of disease in old 
subjects [118], whereas middle aged individuals (35-65 years) are 
heavily affected by overweight. 
 Longevity results from the combination of environment, 
genetic, epigenetic and stochastic components [119], therefore it is 
possible to envisage interventions from the environment that can 
help in retarding the ageing process [120]. To this end, the use of 
vitamins, minerals and phytochemicals (polyphenols and 
carotenoids) could be considered, as the major dietary antioxidants. 
Evidence of epidemiological associations between vitamins and 
disease have been found for nine vitamins. In observational studies, 
people with a high intake of antioxidant vitamins by regular diet or 
as food supplements generally have a lower risk of major chronic 
disease, such as myocardial infarction or stroke, than people who 
are low consumers of antioxidant vitamins [119,120]. Vitamin D is 
associated with a decreased occurrence of fractures when taken 
with calcium. It is known that the immune system contributes to the 
development of osteoporosis and a possible mechanism is through 
the chronic up-regulation of pro-inflammatory cytokines which is 
superimposed with the effects of vitamin D and hormones such as 
estrogens [121]. Thus, supplementation with vitamin D could have 
a more general effect on immunosenescence, besides the specific 
effect on bone metabolism. In addition, new evidences in animal 
model suggest that vitamin D3 acts as an anti-inflammatory agent, 
thus being useful for different age-associated diseases, such as AD 
[122]. Zinc, betacarotene, and vitamin E appear to slow the pro-
gression of macular degeneration, but do not reduce its incidence. 
Vitamin E and lycopene may decrease the risk of prostate cancer 
[122]. In other randomized controlled trials, the apparent beneficial 
results of a high intake of antioxidant vitamins seen in obser-
vational studies have not been confirmed. However, there is 
increasing concern from these trials that pharmacological supple-
mentation of vitamins may be associated with a higher mortality 
risk [123]. On the whole, the role of diet on oxidative stress 
biomarkers remains unclear and represents a potentially fruitful 
area for further research in the health area [124]. 
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 In addition to vitamins and mineral micronutrients, other food 
components endowed with pharmacological properties can have a 
potential effect on health and longevity. As an example, many 
studies indicate that curcumin, the yellow pigment from the 
rhizoma of Curcuma longa, widely used as a spice, is endowed with 
a variety of biological activities: anti-inflammatory, anti-oxidative 
and anti-proliferative [125]. Since oxidative stress and inflam-
mation are major determinants of the ageing process, curcumin can 
have a more general effect that slows down the rate of ageing [126]. 
The potentialities to use curcumin as a possible pharmaceutical tool 
to delay the ageing process depend on its capacity to act on many 
molecular targets with a very broad range of biological actions, as a 
pleiotropic factor, as well as its effects as xenohormetic agent, since 
it activates a sort of stress response in mammalian cells. Curcumin 
can counteract the pro-inflammatory state which is believed to 
participate in many age-related diseases. In fact, it seems that 
curcumin directly affects a few major targets, just like radical 
scavenging and production and the NF-B signaling pathways, 
which can in turn suppress the pro-inflammatory state involved in 
the etiology of ageing and age-related diseases [125]. Moreover, 
resveratrol, a phytochemical contained in many fruits such as black 
grapes and in red wine, has been shown to influence lifespan in 
animal models by lowering inflammatory-oxidative status, but 
further studies are needed to establish its positive role in humans 
[127]. 
3.5. Physical Exercise  
 At present it is clear that the most efficient method that has 
been used to counteract age-related muscle weakness and decrease 
morbidity and mortality is long term physical exercise [128], 
although the exact regime which should be used has not yet been 
defined. 
 A possible explanation for the positive health benefits of an 
active lifestyle and the negative health effects of a sedentary life-
style come from studies by Pedersen and colleagues [67,129]. 
Indeed, they demonstrated that exercise-deprivation induced a 
cluster of physiological abnormalities, similar to metabolic 
syndrome (such as insulin resistance, impaired glucose uptake and 
hyperlipidemia). Moreover, exercise also significantly alters muscle 
gene expression [130]. Thus, it has been proposed that active 
muscle might secrete one or more factors such as myokines that 
mediate important changes in gene expression. One of such factors 
could be IL-6, despite its well known role in the pro-inflammatory 
pathways. Muscle contraction directly stimulates release of IL-6, 
which in turn stimulates sequential release of IL-1ra and IL-10, and 
trained muscle (i.e., muscle with low glycogen content) releases 
more IL-6 than untrained muscle [130,131]. Although IL-6 media-
tes some of the physiological effects of exercise, other factors are 
likely to play a role in this process, such as TNF-, IL-18 and/or 
brain-derived neurotrophic factors, thus suggesting that skeletal 
muscle and specifically physical exercise could be considered as 
mediators to counteract inflamm-ageing at systemic level [132]. 
Indeed, it is widely recognized that regular, moderate exercise 
reduced the risk of infection compared with a sedentary lifestyle, 
whereas prolonged, heavy intensity exercise increased infection 
risk; the so called “J shaped model” [133]. Recent epidemiological 
studies indicate that individuals who maintain a physically active 
lifestyle show an improved glucose metabolism [134].  
 Physical training has beneficial effects on body weight, on 
serum lipid levels, on psychosocial stress, on high blood pressure, 
on insulin resistance and type 2 diabetes. Physical exercise has also 
anti-inflammatory effects counteracting atherogenesis, angiogenesis 
and thrombosis. Moreover, physical exercise increases protein 
synthesis and turnover, increases satellite cell number, stimulates 
appetite, increases hormone levels including IGF-1 which mediates 
many positive effects in combating muscle weakness [135,136]. To 
this regard, supplemental mIGF-1 creates a qualitatively different 
microenvironment for sustaining more efficient muscle regene-
ration and repair [137].  
4. CONCLUSIONS AND PERSPECTIVES  
 The low-grade inflammatory process that occurs with age, 
“inflamm-ageing”, does not have a unique origin, but it could be 
considered as the result of the contribution of many different factors 
and molecules, as simplified in Fig. (1). The first type of effect is 
organ- restricted. This is the case of brain in which dementia (or 
AD) may develop, or the case of liver with hepatitis or cirrhosis, or 
the case of muscle with sarcopenia, amongst others. The second 
type of effect is at systemic level, with the onset and progression of 
age-related pathologies such as cardiovascular diseases and cancer, 
which are the main causes of death in the industrialised countries. 
The site-restricted inflammation could become systemic as a 
consequence of long lasting release of inflammatory mediators in 
presence of favouring genetics/epigenetics variants [2,7]. In this 
contest, only anti-inflammatory strategies may be useful to face this 
biological mechanism underpinning the major age-related diseases 
[138]. 
 Age-related changes at hormonal level are crucial for their 
effects in the inflammatory status and, in particular, cortisol has a 
profound impact on immune activity with anti-inflamm-ageing 
effects, as recently reviewed [139]. The interaction of “inflamm-
ageing/anti-inflamm-ageing” results in a very complex physiolo-
gical regulation of different molecules and contributors such as 
immune system, muscle, liver, adipose tissue and gut microbiota, 
amongst other. Indeed these organs undergo a different ageing as 
recently conceptualised [140] and the presence of senescent cells 
inside organs and tissues may further contribute to the release of 
other inflammatory mediators. In fact, cell senescence leads to a 
coordinated secretion of a large number of soluble factors, the so 
called secretory phenotype, and this occurs in different cell types, 
following different stressors, that may be associated with the 
induction of a pro-inflammatory program [141,142]. However we 
did not discuss this point because it is not yet clear if these 
mediators have a systemic effect or they only act locally in an 
autocrine-paracrine manner.  
 Currently, the signalling circuitry and the cross-talk among the 
various organs, tissues and ecosystems involved are far from being 
clear. In this composite scenario, we believe that systems biology 
represents one of the most powerful and comprehensive approach to 
disentangle the complexity of chronic age-related inflammation, for 
example by focusing on the role of and the interaction between the 
immune system, adipose tissue, muscle, brain, liver and gut 
microbiota in the development, and persistence of inflammation 
over time [143].  
 Is “inflamm-ageing” compatible with longevity (100 years of 
age or more)? The answer is positive and apparently paradoxical, 
since, even if centenarians have an increased level of inflammatory 
mediators in comparison to old subjects and they are very frail, they 
also have high level of anti-inflammatory cytokines together with 
protective genotypes [3]. Therefore, we think that the most proper 
approach to tackle and contain age-related inflammation, “inflamm-
ageing”, is not only to identify the more suitable chemical thera-
pies, but also to better identify the physiological molecules that 
likely are more present in long lived subjects and influence at the 
same time different organs of the body with pleiotropic charac-
teristics. Indeed, since inflamm-ageing is a pleiotropic process 
where many different factors interact, in the same way pleiotropic 
interventions acting concomitantly on different targets and at 
different levels are to be preferred and chosen. 
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IFN = Interferon 
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MCP = Monocyte Chemoattractant Protein 
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